This message was sent to ##Email##
Advertisement
|
|
|
|
| |
Sometimes we all procrastinate – so we've extended our Early Bird Registration rate until Wednesday, Oct. 23 to give you an opportunity to get the best rate for the best transplant nursing conference! Register online and don't forget to book your hotel accommodations at the DoubleTree at Universal Studios.
And if you'd like to arrive in Orlando a little earlier to enjoy the sun and warm weather, join us for our CCTC/CCTN Review Course and incredible Pre-Symposium offerings!
Medical Xpress
If Roland Henry had died in a different part of the country, his organs might have been recovered. And lives could have been saved.
But the local organ collection agency said no. It gave no reason, no explanation to his family, though the Connecticut man appeared to be a well-qualified donor despite advancing age: He died in a hospital, on a ventilator, previously healthy until a car crash that led to a stroke.
"It was devastating to be told there was nothing they considered worthy of donation. Nada. Not a kidney, not a liver, not tissue," recalled Henry's daughter, Donna Cryer, president of the nonprofit Global Liver Institute and herself a recipient of a liver transplant.
Henry's case illustrates troubling uncertainty in a transplant system run by government contractors that are under fire for letting potentially usable organs go to waste.
READ MORE
 |
|
Promoted by
Veloxis Pharmaceuticals
Follow the journeys of kidney transplant patients who transitioned to a different immunosuppression regimen. After talking with their doctors about their experiences with other options, they decided to make a switch.
Watch video
|
|
Yale Daily News
The story of life does not end with death, but in some cases, death is where the law ends, according to a new article published in the Journal of Medical Ethics.
First published online on Sept. 28, the article examines the ethics of testing manufactured organs on brain-dead individuals. The authors, hailing from Yale and New York University, provided guidance on conducting this kind of research to United Therapeutics Corporation and concluded that practices should be drawn from existing research areas’ systems.
READ MORE
Healio
While the executive order signed by president Donald J. Trump last July to set new goals for increasing transplant rates has garnered most of the attention in the kidney community, CMS has been working behind the scenes on new interpretive guidelines for surveyors that will affect transplant center operations, including staff education and processes prior to the transplant.
READ MORE
Advertisement
Veloxis Pharmaceuticals
Did you know there’s a transplant support system to help patients and providers with best-in-class assistance and resources? This ongoing support system assists with benefit investigation, prior authorization assistance, coordination with specialty pharmacies, prescription fulfillment navigation, and CoverMyMeds® access. There’s also a $0 co-pay card to overcome financial barriers.
Find out more
|
Medical Journal of Australia via Medical Xpress
Over a quarter of patients returning to Australia after receiving an organ transplantation overseas will experience complications, including bacterial and viral infections, according to research published online] by the Medical Journal of Australia.
READ MORE
Infectious Disease Advisor
Bloodstream infections are common in patients who have received a solid organ transplants. Approximately half of such cases occur within the first six months post-transplant, and are associated with significant long- and short-term mortality, according to research presented at IDWeek 2019, held from Oct. 2 to Oct. 6, in Washington, DC.
READ MORE
American Journal of Transplantation
Consistent induction of donor‐specific unresponsiveness in the absence of continuous immunosuppressive therapy and toxic effects remains a difficult task in clinical organ transplantation. Transplant immunologists have developed numerous experimental treatments that target antigen‐presentation, costimulation and cytokine production to establish transplantation tolerance.
READ MORE
2 Minute Medicine
This phase 2, parallel-group randomized control trial compared the safety and efficacy profile of maribavir versus valgancicvlovir among patients who received solid organ transplants, finding that both medications had comparable efficacy profiles in preventing CMV infection within six weeks of starting therapy.
READ MORE
JAMA via MD Linx
In order to assess the long-term outcomes of transplant recipients of donor lungs treated with ex vivo lung perfusion, researchers performed a retrospective cohort single-center study of 706 recipients of donor lungs not undergoing EVLP and 230 recipients of donor lungs undergoing EVLP.
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
